Phase 4 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older, able to understand the study procedures, and willing to provide written consent to participate
- People who have been diagnosed with endometrial cancer, confirmed through a tissue or cell sample
- People with a general health and activity level rated as 0, 1, or 2 on a standard medical scale (meaning they are fully active, have some limits on strenuous activity, or are up and about more than half the day — confirm with trial site)
- People whose overall health is good enough for their doctor to consider them suitable to receive a taxane-platinum chemotherapy combination, with or without immunotherapy
- People who have not previously received chemotherapy treatment
- People who could potentially become pregnant must have a negative pregnancy test at the start and agree to use effective birth control during the study and for 6 months after the last dose, including monthly pregnancy testing throughout the study
Who may not be able to join:
- People who experience vomiting in the 24 hours before their first chemotherapy session
- People who are scheduled to receive radiation therapy to the abdomen or pelvis within one week before starting the study, or between day 1 and day 5
- People who are scheduled to undergo a bone marrow or stem cell transplant
- People who regularly use corticosteroid medications (a type of steroid medicine) on an ongoing basis
- People who have cancer that has spread to the brain
- People with a serious or uncontrolled medical condition that their doctor considers a significant health risk
- People with a history of, or known tendency toward, certain heart rhythm problems or serious heart or cardiovascular disease
- People who are pregnant, breastfeeding, or planning to become pregnant during the study period or within 180 days after the last dose of study treatment
- People with a known allergy or medical reason why they cannot take the study drugs or any of their ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Monika Ducceschi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phone: +39 02 2390 2342
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Effectiveness
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.